



Supplementary Figure 1 Deleting *Scap* did not cause a significant phenotype in growth plate chondrocytes.



Supplementary Figure 1: Deleting *Scap* did not cause a significant phenotype in growth plate chondrocytes. (A) Safranin O staining of *Scap^{fl/fl}* and *Col2a1Cre^{ERT2};Scap^{fl/fl}* hind limbs at 6 month. (B) Representative immunohistochemistry of SOX9. (C) Representative immunohistochemistry of type X collagen. (D) Representative immunohistochemistry of Ki67. Scale bar, 200 μ m.

Supplementary Figure 2: Lovastatin inhibits chondrosarcoma growth in vivo.



Supplementary Figure 2: Lovastatin inhibits chondrosarcoma growth in vivo. (A) Percentage of BrdU positive cells in the control group and lovastatin treatment group of five different patient derived tumor xenografts. (B) Percentage of cleaved caspase 3 positive cells in the control group and lovastatin treatment group of five different patient derived tumor xenografts. For each patient-derived xenograft, n=5. *p<0.05, **p<0.01, ***p<0.001. p-value was determined by unpaired, two-tailed student t-test. Means ± 95% confidence intervals were shown.